Literature DB >> 26330427

New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype.

Jamie Lim1, Neal M Poulin1, Torsten O Nielsen2.   

Abstract

There are more than 100 sarcoma subtypes, each uncommon and diagnostically challenging. Conventional chemotherapy has little benefit for most soft-tissue sarcomas; new treatment strategies are needed. Multiple recent genomic studies have provided detailed insights into sarcoma biology, including more accurate classification by molecular subtype, identification of recurrent mutations in oncogenic pathways, and evidence of epigenetic dysregulation. Advances in immunotherapy (adoptive immune cell transfer, tumor vaccine strategies, and immune checkpoint inhibition) have also provided a better understanding of how immuno-oncology might best be applied to sarcoma treatment, including connections to oncogenic pathways that may support combination strategies with conventional and targeted therapies. In this article, we review the latest sarcoma genomic studies and immuno-oncology developments and discuss how the findings suggest potential strategies to improve diagnosis and treatment across multiple sarcoma subtypes. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26330427     DOI: 10.1158/1078-0432.CCR-15-0831

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  TGFβ and Hippo Pathways Cooperate to Enhance Sarcomagenesis and Metastasis through the Hyaluronan-Mediated Motility Receptor (HMMR).

Authors:  Shuai Ye; Ying Liu; Ashley M Fuller; Rohan Katti; Gabrielle E Ciotti; Susan Chor; Md Zahidul Alam; Samir Devalaraja; Kristin Lorent; Kristy Weber; Malay Haldar; Michael A Pack; T S Karin Eisinger-Mathason
Journal:  Mol Cancer Res       Date:  2020-01-27       Impact factor: 5.852

2.  Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.

Authors:  Emily Z Keung; Jen-Wei Tsai; Ali M Ali; Janice N Cormier; Andrew J Bishop; B Ashleigh Guadagnolo; Keila E Torres; Neeta Somaiah; Kelly K Hunt; Jennifer A Wargo; Alexander J Lazar; Wei-Lien Wang; Christina L Roland
Journal:  Oncoimmunology       Date:  2017-10-31       Impact factor: 8.110

3.  YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.

Authors:  Shuai Ye; Matthew A Lawlor; Adrian Rivera-Reyes; Shaun Egolf; Susan Chor; Koreana Pak; Gabrielle E Ciotti; Avery C Lee; Gloria E Marino; Jennifer Shah; David Niedzwicki; Kristy Weber; Paul M C Park; Md Zahidul Alam; Alison Grazioli; Malay Haldar; Mousheng Xu; Jennifer A Perry; Jun Qi; T S Karin Eisinger-Mathason
Journal:  Cancer Res       Date:  2018-02-28       Impact factor: 12.701

4.  Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.

Authors:  Lixin Wan; Kexin Xu; Yongkun Wei; Jinfang Zhang; Tao Han; Christopher Fry; Zhao Zhang; Yao Vickie Wang; Liyu Huang; Min Yuan; Weiya Xia; Wei-Chao Chang; Wen-Chien Huang; Chien-Liang Liu; Yuan-Ching Chang; Jinsong Liu; Yun Wu; Victor X Jin; Xiangpeng Dai; Jianfeng Guo; Jia Liu; Shulong Jiang; Jin Li; John M Asara; Myles Brown; Mien-Chie Hung; Wenyi Wei
Journal:  Mol Cell       Date:  2018-01-18       Impact factor: 17.970

Review 5.  Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.

Authors:  Adrián Mariño-Enríquez; Judith V M G Bovée
Journal:  Surg Pathol Clin       Date:  2016-09

6.  Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.

Authors:  Marie Kostine; Arjen Hg Cleven; Noel F C C de Miranda; Antoine Italiano; Anne-Marie Cleton-Jansen; Judith V M G Bovée
Journal:  Mod Pathol       Date:  2016-06-17       Impact factor: 7.842

7.  High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas.

Authors:  Sha Lou; Arjen H G Cleven; Benjamin Balluff; Marieke de Graaff; Marie Kostine; Inge Briaire-de Bruijn; Liam A McDonnell; Judith V M G Bovée
Journal:  Clin Sarcoma Res       Date:  2016-10-01

8.  Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.

Authors:  Marie Kostine; Inge H Briaire-de Bruijn; Arjen H G Cleven; Carly Vervat; Willem E Corver; Marco W Schilham; Els Van Beelen; Hester van Boven; Rick L Haas; Antoine Italiano; Anne-Marie Cleton-Jansen; Judith V M G Bovée
Journal:  Oncoimmunology       Date:  2017-10-26       Impact factor: 8.110

9.  Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.

Authors:  L Paoluzzi; A Cacavio; M Ghesani; A Karambelkar; A Rapkiewicz; J Weber; G Rosen
Journal:  Clin Sarcoma Res       Date:  2016-12-30

Review 10.  Anti-angiogenesis target therapy for advanced osteosarcoma (Review).

Authors:  Lu Xie; Tao Ji; Wei Guo
Journal:  Oncol Rep       Date:  2017-06-21       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.